Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds
Open Access
- 23 February 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (2), e17132
- https://doi.org/10.1371/journal.pone.0017132
Abstract
Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional chemotherapy treatment. These formulations are associated with problems like severe toxic side effects on healthy organs, drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site-specific controlled drug delivery systems. In response to these concerns, we have developed a new drug delivery system based on magnetic erythrocytes engineered with a viral spike fusion protein. This new erythrocyte-based drug delivery system has the potential for magnetic-controlled site-specific localization and highly efficient fusion capability with the targeted cells. Here we show that the erythro-magneto-HA virosomes drug delivery system is able to attach and fuse with the target cells and to efficiently release therapeutic compounds inside the cells. The efficacy of the anti-cancer drug employed is increased and the dose required is 10 time less than that needed with conventional therapy.This publication has 42 references indexed in Scilit:
- Prodrug cancer gene therapyCancer Letters, 2008
- Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivativesJournal of Controlled Release, 2008
- Pharmacokinetics and biodistribution of amikacin encapsulated in carrier erythrocytesJournal of Antimicrobial Chemotherapy, 2007
- Applications of carrier erythrocytes in delivery of biopharmaceuticalsJournal of Controlled Release, 2007
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Recent advances on chitosan-based micro- and nanoparticles in drug deliveryJournal of Controlled Release, 2004
- Drug Delivery Systems: Entering the MainstreamScience, 2004
- 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapyOncogene, 2002
- Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotidesGene Therapy, 2002
- Capture of Stealth Nanoparticles by the Body’s DefencesCritical Reviews in Therapeutic Drug Carrier Systems, 2001